{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:59:11Z","timestamp":1772863151531,"version":"3.50.1"},"reference-count":90,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T00:00:00Z","timestamp":1287446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1000352","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T20:28:05Z","timestamp":1287520085000},"page":"e1000352","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":346,"title":["Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review"],"prefix":"10.1371","volume":"7","author":[{"given":"Geoffrey K.","family":"Spurling","sequence":"first","affiliation":[]},{"given":"Peter R.","family":"Mansfield","sequence":"additional","affiliation":[]},{"given":"Brett D.","family":"Montgomery","sequence":"additional","affiliation":[]},{"given":"Joel","family":"Lexchin","sequence":"additional","affiliation":[]},{"given":"Jenny","family":"Doust","sequence":"additional","affiliation":[]},{"given":"Noordin","family":"Othman","sequence":"additional","affiliation":[]},{"given":"Agnes I.","family":"Vitry","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2010,10,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1371\/journal.pmed.0050001","article-title":"The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States.","volume":"5","author":"MA Gagnon","year":"2008","journal-title":"PLoS Med"},{"key":"ref2","article-title":"L'information des m\u00e9decins g\u00e9n\u00e9ralistes sur le m\u00e9dicament.","author":"PL Bras"},{"key":"ref3","article-title":"Advertising and promotion of drugs.","author":"P Garai","year":"1964"},{"key":"ref4","article-title":"Code on Interactions with Healthcare Professionals."},{"key":"ref5","first-page":"305","article-title":"Understanding why GPs see pharmaceutical representatives: a qualitative interview study.","volume":"53","author":"H Prosser","year":"2003","journal-title":"Br J Gen Pract"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11606-006-0041-z","article-title":"Physicians and drug representatives: exploring the dynamics of the relationship.","volume":"22","author":"S Chimonas","year":"2007","journal-title":"J Gen Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11606-009-0989-6","article-title":"Prescribers and pharmaceutical representatives: why are we still meeting?","volume":"24","author":"MA Fischer","year":"2009","journal-title":"J Gen Intern Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0002-9343(01)00660-X","article-title":"Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions.","volume":"110","author":"MA Steinman","year":"2001","journal-title":"Am J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/pds.884","article-title":"Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey.","volume":"12","author":"P Rutledge","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/jme.2005.014480","article-title":"Interactions of doctors with the pharmaceutical industry.","volume":"32","author":"MA Morgan","year":"2006","journal-title":"J Med Ethics"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMhpr042734","article-title":"Doctors and drug companies.","volume":"351","author":"D Blumenthal","year":"2004","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jama.2009.407","article-title":"Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.","volume":"301","author":"DJ Rothman","year":"2009","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1371\/journal.pmed.0030451","article-title":"Educating health professionals about drug and device promotion: advocates' recommendations.","volume":"3","author":"PR Mansfield","year":"2006","journal-title":"PLoS Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e6350","DOI":"10.1371\/journal.pone.0006350","article-title":"Quality of pharmaceutical advertisements in medical journals: a systematic review.","volume":"4","author":"N Othman","year":"2009","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2458-8-167","article-title":"Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study.","volume":"8","author":"BD Montgomery","year":"2008","journal-title":"BMC Public Health"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/jama.1995.03520400066047","article-title":"The accuracy of drug information from pharmaceutical sales representatives.","volume":"273","author":"MG Ziegler","year":"1995","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2923.1977.tb00595.x","article-title":"Content analysis of drug-detailing by pharmaceutical representatives.","volume":"11","author":"E Hemminki","year":"1977","journal-title":"Med Educ"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jama.283.3.373","article-title":"Physicians and the pharmaceutical industry: is a gift ever just a gift?","volume":"283","author":"A Wazana","year":"2000","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1525-1497.2005.0134.x","article-title":"Interactions between pharmaceutical representatives and doctors in training. A thematic review.","volume":"20","author":"DA Zipkin","year":"2005","journal-title":"J Gen Intern Med"},{"key":"ref20","first-page":"785","article-title":"The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review.","volume":"5","author":"P Manchanda","year":"2005","journal-title":"Yale J Health Policy Law Ethics"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch8","article-title":"Assessing risk of bias in included studies.","author":"J Higgins","year":"2008"},{"key":"ref22","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis.","author":"G Wells","year":"2005"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies.","volume":"7","author":"JJ Deeks","year":"2003","journal-title":"Health Technol Assess"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"DF Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0277-9536(03)00150-3","article-title":"The drug industry and medical practice\u2013the case of menopausal hormone therapy in Estonia.","volume":"58","author":"E Hemminki","year":"2004","journal-title":"Soc Sci Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/875512259200800108","article-title":"Impact of pharmaceutical sales representatives on physician antibiotic prescribing.","volume":"8","author":"JD Cleary","year":"1992","journal-title":"J Pharm Technol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/10401230109148963","article-title":"Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits.","volume":"13","author":"TL Schwartz","year":"2001","journal-title":"Ann Clin Psychiatry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1378\/chest.102.1.270","article-title":"The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch.","volume":"102","author":"JP Orlowski","year":"1992","journal-title":"Chest"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5694\/j.1326-5377.2008.tb01497.x","article-title":"The effect of advertising in clinical software on general practitioners' prescribing behaviour.","volume":"188","author":"J Henderson","year":"2008","journal-title":"Med J Aust"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.socscimed.2006.07.019","article-title":"Determinants for the adoption of angiotensin II receptor blockers by general practitioners.","volume":"63","author":"JP Greving","year":"2006","journal-title":"Soc Sci Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1176\/ps.2007.58.7.983","article-title":"Adding or switching antipsychotic medications in treatment-refractory schizophrenia.","volume":"58","author":"J Kreyenbuhl","year":"2007","journal-title":"Psychiatr Serv"},{"key":"ref32","first-page":"139","article-title":"The antibiotic prescribing behaviourof physicians for acute tonsillopharyngitis in primary care.","volume":"44","author":"H Canli","year":"2006","journal-title":"Ethiop Med J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0277-9536(88)90149-9","article-title":"The role of commercial sources in the adoption of a new drug.","volume":"26","author":"MY Peay","year":"1988","journal-title":"Soc Sci Med"},{"key":"ref34","article-title":"[Influence de la publicit\u00e9 pharmaceutique sur la prescription.] Influence of pharmaceutical advertising on prescription [MD dissertation]","author":"O Charbit","year":"2003"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2125.2000.00126.x","article-title":"Sleeping with the enemy? A randomized controlled trial of a collaborative health authority\/industry intervention to influence prescribing practice.","volume":"49","author":"N Freemantle","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/009286159903300411","article-title":"Promoting optimal antibiotic therapy for otitis media using commercially sponsored evidence-based detailing: A prospective controlled trial.","volume":"33","author":"L Dolovich","year":"1999","journal-title":"Drug Information Journal"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1001\/jama.295.23.2759","article-title":"How conducting a clinical trial affects physicians' guideline adherence and drug preferences.","volume":"295","author":"M Andersen","year":"2006","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jama.1994.03510330062035","article-title":"Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary.","volume":"271","author":"MM Chren","year":"1994","journal-title":"JAMA"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00001888-199601000-00022","article-title":"When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?","volume":"71","author":"RW Spingarn","year":"1996","journal-title":"Acad Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1287\/mnsc.1070.0718","article-title":"The debate on influencing doctors' decisions: are drug characteristics the missing link?","volume":"53","author":"S Venkataraman","year":"2007","journal-title":"Manage Sci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hec.1007","article-title":"Pharmaceutical promotion and GP prescription behaviour.","volume":"15","author":"F Windmeijer","year":"2006","journal-title":"Health Econ"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1287\/mksc.1030.0029","article-title":"Strategic detailing and pricing behaviour in international markets.","volume":"24","author":"P Chintagunta","year":"2005","journal-title":"Marketing Science"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1509\/jmkr.2005.42.3.278","article-title":"Temporal differences in the role of marketing communication in new product categories.","volume":"42","author":"S Narayanan","year":"2005","journal-title":"J Marketing Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1509\/jppm.23.2.115.51395","article-title":"Effects of direct-to-consumer advertising on medication choice: the case of anti-depressants.","volume":"23","author":"J Donohue","year":"2004","journal-title":"J Public Policy Mark"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1287\/mnsc.1040.0281","article-title":"Are physicians \u201ceasy marks\u201d? quantifying the effects of detailing and sampling on new prescriptions.","volume":"50","author":"N Mizik","year":"2004","journal-title":"Manage Sci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/B:MARK.0000047389.93584.09","article-title":"Responsiveness of physician prescription behaviour to salesforce effort: an individual level analysis.","volume":"15","author":"P Manchanda","year":"2004","journal-title":"Market Lett"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1509\/jmkr.41.4.467.47005","article-title":"Response modeling with nonrandom marketing-mix variables.","volume":"41","author":"P Manchanda","year":"2004","journal-title":"J Marketing Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1467-6451.00200","article-title":"Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs.","volume":"L1","author":"E Berndt","year":"2003","journal-title":"The J Ind Econ"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1162\/105864002320757262","article-title":"Do pharmaceutical sales respond to scientific evidence?","volume":"11","author":"P Azoulay","year":"2002","journal-title":"J Econ Manage Str"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1086\/467419","article-title":"Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs.","volume":"42","author":"J Rizzo","year":"1999","journal-title":"J Law Econ"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/467158","article-title":"Persuasion or information? promotion and the shares of brand name and generic pharmaceuticals.","volume":"31","author":"M Hurwitz","year":"1988","journal-title":"J Law Econ"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/0277-9536(85)90197-2","article-title":"Effects of promotion on pharmaceutical demand.","volume":"20","author":"JI Mackowiak","year":"1985","journal-title":"Soc Sci Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/466973","article-title":"Persuasion or information? the economics of prescription drug advertising.","volume":"24","author":"K Leffler","year":"1981","journal-title":"J Law Econ"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1086\/466818","article-title":"The theory of supply with applications to the ethical pharmaceutical industry.","volume":"18","author":"L Telser","year":"1975","journal-title":"J Law Econ"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/qshc.2006.020164","article-title":"General practitioners and pharmaceutical sales representatives: quality improvement research.","volume":"16","author":"G Spurling","year":"2007","journal-title":"Qual Saf Health Care"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.291.1.54","article-title":"Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996\u20132002.","volume":"291","author":"RS Stafford","year":"2004","journal-title":"JAMA"},{"key":"ref57","article-title":"La diffusion de l'innovation pharmaceutique en m\u00e9dicine lib\u00e9rale: revue de la litt\u00e9rature et premiers r\u00e9sultants fran\u00e7ais.","volume":"73","author":"L Auvray","year":"2003","journal-title":"Bulletin d'information en \u00e9conomie de la sant\u00e9"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2105\/AJPH.77.12.1518","article-title":"Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene.","volume":"77","author":"SB Soumerai","year":"1987","journal-title":"Am J Public Health"},{"key":"ref59","first-page":"977","article-title":"Impact of Dear Doctor letters on prescribing: evaluation of the use of tramadol HCl.","volume":"32","author":"R Kazmierczak","year":"1997","journal-title":"Formulary"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/chp.4750080104","article-title":"Changes in drug prescribing patterns related to commercial company funding of continuing medical education.","volume":"8","author":"MA Bowman","year":"1988","journal-title":"J Contin Educ Health Prof"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1472-6963-7-132","article-title":"Determinants of the range of drugs prescribed in general practice: a cross-sectional analysis.","volume":"7","author":"DH de Bakker","year":"2007","journal-title":"BMC Health Serv Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1371\/journal.pmed.0040134","article-title":"Characteristics and impact of drug detailing for gabapentin.","volume":"4","author":"MA Steinman","year":"2007","journal-title":"PLoS Med"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2005.02.001","article-title":"Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care.","volume":"77","author":"H Verdoux","year":"2005","journal-title":"Schizophr Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/fampra\/cmi074","article-title":"Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives.","volume":"22","author":"PE Muijrers","year":"2005","journal-title":"Fam Pract"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1176\/appi.ap.29.5.500","article-title":"The association of pharmaceutical company promotional spending with resident physician prescribing behavior.","volume":"29","author":"FY Huang","year":"2005","journal-title":"Acad Psychiatry"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/qhc.12.1.29","article-title":"Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey.","volume":"12","author":"C Watkins","year":"2003","journal-title":"Qual Saf Health Care"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/fampra\/cmg516","article-title":"New drug uptake: qualitative comparison of high and low prescribing GPs' attitudes and approach.","volume":"20","author":"H Prosser","year":"2003","journal-title":"Fam Pract"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/eurpub\/12.3.187","article-title":"Influence of commercial information on prescription quantity in primary care.","volume":"12","author":"F Caamano","year":"2002","journal-title":"Eur J Public Health"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1509\/jmkg.65.3.79.18329","article-title":"Promotion of prescription drugs and its impact on physicians' choice behaviour.","volume":"65","author":"F Gonul","year":"2001","journal-title":"J Marketing"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2710.1999.00255.x","article-title":"A survey of the advertising of nine new drugs in the general practice literature.","volume":"24","author":"M Jones","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archfami.5.4.201","article-title":"Physicians, pharmaceutical sales representatives, and the cost of prescribing.","volume":"5","author":"TS Caudill","year":"1996","journal-title":"Arch Fam Med"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF00196105","article-title":"The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice.","volume":"46","author":"D Berings","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF02600542","article-title":"Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff.","volume":"5","author":"N Lurie","year":"1990","journal-title":"J Gen Intern Med"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/0277-9536(82)90158-7","article-title":"Rational prescribing and sources of information.","volume":"16","author":"F Haayer","year":"1982","journal-title":"Soc Sci Med"},{"key":"ref75","first-page":"39","article-title":"Ad recognition and prescribing by physicians.","volume":"20","author":"H Walton","year":"1980","journal-title":"J Advertising Res"},{"key":"ref76","first-page":"538","article-title":"Drug advertising and prescribing.","volume":"28","author":"R Dajda","year":"1978","journal-title":"J R Coll Gen Pract"},{"key":"ref77","first-page":"118","article-title":"Differential education concerning therapeutics and resultant physician prescribing patterns.","volume":"47","author":"MH Becker","year":"1972","journal-title":"J Med Educ"},{"key":"ref78","article-title":"The effects of detailing on prescribing decisions under two-sided learning.","author":"A Ching","year":"2007"},{"key":"ref79","doi-asserted-by":"crossref","DOI":"10.2202\/1558-9544.1044","article-title":"Demand effects of recent changes in prescription drug promotion","author":"M Rosenthal","year":"2003"},{"key":"ref80","article-title":"The effect of journal advertising on market shares of new prescriptions","year":"1989"},{"key":"ref81","article-title":"Prescription behaviour of 358 Flemish general practitioners.","author":"L Blondeel","year":"1987"},{"key":"ref82","article-title":"Year of graduation, level of \u201cscepticism\u201d and attendance at sponsored meetings are significant predictors of General Practioners' beliefs about the appropriateness of drugs","author":"P Mansfield","year":"2000"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11129-010-9082-z","article-title":"The effects of detailing on prescribing decisions under quality uncertainty.","volume":"8","author":"A Ching","year":"2010","journal-title":"Quant Mark Econ"},{"key":"ref84","article-title":"Marketing planning for the pharmaceutical industry","author":"J Lidstone","year":"1987"},{"key":"ref85","article-title":"Deception by design: pharmaceutical promotion in the third world","author":"J Lexchin","year":"1995"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2458-7-122","article-title":"Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey.","volume":"7","author":"S Vancelik","year":"2007","journal-title":"BMC Public Health"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1370\/afm.259","article-title":"The company we keep: why physicians should refuse to see pharmaceutical representatives.","volume":"3","author":"H Brody","year":"2005","journal-title":"Ann Fam Med"},{"key":"ref88","article-title":"American Medical Student's Association."},{"key":"ref89","article-title":"No Free Lunch."},{"key":"ref90","doi-asserted-by":"crossref","first-page":"11A","DOI":"10.1002\/ana.21100","article-title":"Marketing and drug costs: who is laughing and crying?","volume":"61","author":"SC Johnston","year":"2007","journal-title":"Ann Neurol"}],"container-title":["PLoS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1000352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T02:05:45Z","timestamp":1592013945000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1000352"}},"subtitle":[],"editor":[{"given":"David","family":"Henry","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2010,10,19]]},"references-count":90,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2010,10,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1000352","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,19]]}}}